Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

European journal of haematology·2026
Same author

Addition of Daratumumab to First-Line Therapy of Newly Diagnosed Multiple Myeloma in Patients Eligible for Autologous Stem Cell Transplantation: A Single-Center Real-Life Experience.

Mediterranean journal of hematology and infectious diseases·2025
Same author

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.

European journal of haematology·2025
Same author

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Hematological oncology·2025
Same author

Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.

European journal of haematology·2025
Same author

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.

Haematologica·2024

Related Experiment Video

Updated: May 24, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Interpretation and recommended testing for antiphospholipid antibodies.

Monica Galli1

  • 1Divisione di Ematologia, Ospedali Riuniti, Largo Barozzi 1, Bergamo, Italy. monicagalli@virgilio.it

Seminars in Thrombosis and Hemostasis
|March 9, 2012
PubMed
Summary

Antiphospholipid syndrome (APS) involves thrombosis and pregnancy issues linked to antiphospholipid antibodies (aPL). Lupus anticoagulants (LA) are stronger risk factors for thrombosis than anticardiolipin (aCL) or anti-β2-glycoprotein I (aβ2GPI) antibodies.

More Related Videos

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

Related Experiment Videos

Last Updated: May 24, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

Area of Science:

  • Immunology
  • Hematology
  • Obstetrics

Background:

  • Antiphospholipid syndrome (APS) is characterized by thrombosis or pregnancy complications alongside specific antiphospholipid antibodies (aPL).
  • Recent advancements focus on harmonizing laboratory detection of aPL and establishing diagnostic guidelines.
  • Understanding the pathogenic mechanisms and antigenic targets of aPL is crucial for clarifying their prognostic significance.

Purpose of the Study:

  • To review the prognostic significance of different antiphospholipid antibodies (aPL) in Antiphospholipid Syndrome (APS).
  • To highlight the varying risk associated with lupus anticoagulants (LA) versus anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibodies.
  • To emphasize the role of specific aPL profiles in predicting thrombotic and obstetric outcomes.

Main Methods:

  • Review of clinical studies and laboratory detection methods for antiphospholipid antibodies (aPL).
  • Analysis of the association between specific aPL (LA, aCL, aβ2GPI) and clinical outcomes in APS.
  • Evaluation of prognostic factors including LA activity and triple aPL positivity.

Main Results:

  • Lupus anticoagulants (LA) are consistently identified as stronger risk factors for arterial and venous thrombosis compared to anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibodies.
  • LA activity dependent on the first domain of β2-glycoprotein I is a significant predictor of thrombotic risk.
  • Triple aPL positivity (presence of LA, aCL, and aβ2GPI) is associated with increased obstetric risk.

Conclusions:

  • Lupus anticoagulants (LA) represent a heightened risk for thrombosis in Antiphospholipid Syndrome (APS).
  • Specific aPL profiles, such as LA activity linked to β2-glycoprotein I domain I and triple positivity, are key prognosticators.
  • Further knowledge on aPL mechanisms and targets will enhance diagnostic and therapeutic strategies for APS.